Full-Time

Research Associate / Senior Research Associate

Discovery Biology

Superluminal Medicines

Superluminal Medicines

51-200 employees

ML-driven design of candidate small molecules

No salary listed

Boston, MA, USA

In Person

Bachelor's

Category
Biology & Biotech (1)

Get referred to Superluminal Medicines

See people who can refer or advise you

Requirements
  • Bachelor's degree in Biology, Cell Biology, Biochemistry, or a related life sciences discipline
  • Minimum of 1 year of biotechnology or pharmaceutical industry experience
  • Experience working with 384-well plate-based assay formats
  • Experience performing routine mammalian cell culture techniques
  • Experience with plate-based in vitro assays, including one or more of the following technologies: HTRF, luminescence, BRET, or Alpha assays
  • Experience executing cell-based assays, including assay optimization and routine screening campaigns
  • Basic understanding of early-stage drug discovery processes
  • Demonstrated ability to work effectively in a collaborative, cross-functional team environment
Responsibilities
  • Perform routine mammalian cell culture and maintain mammalian cell lines
  • Execute routine cell-based assays to support early-stage drug discovery programs
  • Under the guidance of the manager, assist with the development and optimization of new cell-based assays for screening
  • Generate, analyze, document, and upload experimental data to company databases in a timely and accurate manner
  • Ensure compliance with established laboratory practices, SOPs, and company policies, including both wet lab and electronic data management requirements
Desired Qualifications
  • Experience with laboratory automation and/or semi-automated assay workflows
  • Experience with cell-based assay development and optimization for high-throughput screening
  • Experience in small molecule drug discovery
Superluminal Medicines

Superluminal Medicines

View

Superluminal Medicines develops small-molecule drug discovery solutions by combining deep biology, chemistry, and machine learning. It creates candidate-ready compounds with high speed and accuracy, using a proprietary big data platform and predictive design models to model protein shapes and design selective compounds that induce precise structural changes for therapeutic effects. The company collaborates with pharmaceutical and biotech firms, licensing its technology and pursuing milestone-based payments, rather than selling products outright. This partnership-centric model helps clients accelerate their drug discovery programs in a highly competitive market. The company aims to shorten the path from target to clinical candidate by delivering well-characterized, selective small molecules efficiently.

Company Size

51-200

Company Stage

Series A

Total Funding

$153M

Headquarters

Boston, Massachusetts

Founded

2023

Get referred to Superluminal Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Lilly's February 2026 update reaffirmed up to $1.3B in payments.
  • Superluminal expects an IND submission in late 2026 for obesity.
  • RA Capital, Insight, NVentures, Catalio, and Lilly funded the $120M Series A.

What critics are saying

  • Lilly gets exclusive rights, so Superluminal loses downstream economics.
  • The lead obesity asset still needs 2026 human data after IND filing.
  • A failed MC4R program would crush platform credibility and future partnering.

What makes Superluminal Medicines unique

  • Superluminal combines protein dynamics, structural biology, and ML on GPCRs.
  • Lilly backed the 2024 Series A and signed a 2025 $1.3B pact.
  • Its lead MC4R obesity program entered IND-enabling studies in July 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Wellness Program

Mental Health Support

Gym Membership

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Parental Leave

Relocation Assistance

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Training Programs

Tuition Reimbursement

Meal Benefits

Commuter Benefits

Pet Insurance

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

31%

1 year growth

31%

2 year growth

31%
The Pharma Letter
Aug 15th, 2025
Lilly and Superluminal work on GPCR drugs for cardiometabolic diseases

Eli Lilly (NYSE: LLY) has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule therapies for undisclosed G protein-coupled receptor (GPCR) targets linked to cardiometabolic diseases and obesity.

Fierce Biotech
Aug 14th, 2025
Superluminal secures $1.3B pact with backer Lilly to develop cardiometabolic, obesity drugs

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech. | Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech.

BioWorld
Aug 14th, 2025
Superluminal, Lilly in $1.3B Deal

Superluminal Medicines Inc. has entered a collaboration with Eli Lilly and Co. in a deal worth up to $1.3 billion. The partnership aims to develop therapies for cardiometabolic diseases and obesity by targeting undisclosed G protein-coupled receptors. The deal includes up-front and near-term investments, an equity investment, development and commercial milestones, and tiered royalties on net sales.

BioWorld
Aug 14th, 2025
Superluminal joins a $1.3B deal with series A backer Lilly

Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G protein-coupled receptor targets.

FinSMEs
Sep 9th, 2024
Superluminal Medicines Closes $120M Series A Funding

Superluminal Medicines, a Boston, MA-based company that uses generative biology, chemistry and machine learning approaches to create medicines, raised $120M in Series A funding